Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: Prediction of in vivo drug-drug interactions

European Journal of Clinical Pharmacology

Volumn 55, Issue 11-12, 2000, Pages 843-852

  Katoh, M ^a   Nakajima, M ^a   Shimada, N ^b   Yamazaki, H ^a   Yokoi, T ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b DAIICHI PURE CHEMICALS CO LTD   (Japan)

Author keywords

1,4 Dihydropyridine calcium antagonist; Cytochrome P450; Inhibition

Indexed keywords

1,4 DIHYDROPYRIDINE; AMLODIPINE; ARANIDIPINE; BENIDIPINE; CILNIDIPINE; EFONIDIPINE; FELODIPINE; MANIDIPINE; NICARDIPINE; NIFEDIPINE; NILVADIPINE; NISOLDIPINE; NITRENDIPINE; STEROID 11BETA MONOOXYGENASE;

ARTICLE; CALCIUM ANTAGONISM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CROSS REACTIVITY; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME INHIBITION; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; INHIBITION KINETICS; PREDICTION; PRIORITY JOURNAL;

EID: 0034033399     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050706     Document Type: Article

References (39)

1. Fleckenstein A (1977) Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Ann Rev Pharmacol Toxicol 17: 149-166
2. Godfraind T, Miller R, Wibo M (1986) Calcium antagonism and calcium entry blockade. Pharmacol Rev 38: 321-416
3. Kleinbloesem CH, Harten J, Braummelen P, Breimer DD (1984) Liquid chromatographic determination of nifedipine in plasma and of its main metabolite in urine. J Chromatogr 308: 209-216
4. Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJG (1986) The metabolism of nicardipine hydrochloride in healthy male volunteers. Xenobiotica 16: 341-349
5. 14C]felodipine, a new vasodilating drug, in healthy volunteers. Drugs 34: 43-52
6. 14C-nitrendipine in healthy volunteers. J Cardiovasc Pharmacol 9: 122-128
7. Scherling D, Karl W, Ahr G, Ahr HJ, Wehinger E (1988) Pharmacokinetics of nisoldipine: III. Biotransformation of nisoldipine in rat, dog, monkey, and man. Arzneimittelforschung 38: 1105-1110
8. Beresford AP, McGibney D, Humphrey MJ, Macrae PV, Stopher DA (1988) Metabolism and kinetics of amlodipine in man. Xenobiotica 18: 245-254
9. Guengerich FP (1995) Human cytochrome P450 enzymes. In: Ortiz de Montellano PR (ed) Cytochrome P450: structure, mechanism, and biochemistry. Plenum, New York, pp 473-536
10. Pelkonen O, Mäenpää J, Taavitsainen P, Rautio A, Raunio H (1998) Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica 28: 1203-1253
11. Funaki T, Soons PA, Guengerich FP, Breimer DD (1989) In vivo oxidative cleavage of a pyridine-carboxylic acid ester metabolite of nifedipine. Biochem Pharmacol 38: 4213-4216
12. Guengerich FP (1987) Oxidation cleavage of carboxylic esters by cytochrome P-450. J Biol Chem 262: 8459-8462
13. Guengerich FP, Peterson LA, Böcker RH (1988) Cytochrome P-450-catalyzed hydroxylation and carboxylic acid ester cleavage of Hantzsch pyridine esters. J Biol Chem 263: 8176-8183
14. Rämsch KD, Sommer J (1983) Pharmacokinetics and metabolism of nifedipine. Hypertension 5: 18-24
15. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, Waxman DJ (1986) Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 261: 5051-5060
16. Gonzalez FJ, Schmid BJ, Umeno M, McBride OW, Hardwich JP, Meyer UA, Gelboin HV, Idle JR (1988) Human P450 PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450 PCN1 is nifedipine oxidase. DNA 7: 79-86
17. Guengerich FP, Böcker RH (1988) Cytochrome P-450-catalyzed dehydrogenation of 1,4-dihydropyridines. J Biol Chem 263: 8168-8175
18. Guengerich FP, Brian WR, Iwasaki M, Sari MA, Bäärnhielm C, Berntsson P (1991) Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4. J Med Chem 34: 1838-1844
19. Teramura T, Fukunaga Y, Hoogdalem EJ, Watanabe T, Higuchi S (1997) Examination of metabolic pathways and identification of human liver cytochrome P450 isozymes responsible for the metabolism of barnidipine, a calcium channel blocker. Xenobiotica 23: 885-900
20. Nakajima M, Ohyama K, Nakamura S, Shimada N, Yamazaki H, Yokoi T (1999) Inhibitory effects of azelastine and its metabolites on drug oxidation catalyzed by human cytochrome P450 enzymes. Drug Metab Dispos 27: 792-797
21. Tucker GT (1992) The rational selection of drug interaction studies: implications of recent advances in drug metabolism. Int J Clin Pharmacol Ther Toxicol 30: 550-553
22. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y (1998) Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 50: 387-411
23. Higuchi S, Kawamura N, Fujii N, Kawai M, Odakura T, Arita M, Mashimo N (1981) Plasma concentration of unchanged compound in healthy volunteers after multiple oral administration of nicardipine hydrochloride. Clin Rep 15: 6289-6292
24. Rämsch KD (1981) Pharmacokinetics of nifedipine. Schwerpunkt Medizin 4: 55-61
25. Akioka K, Kohno M, Nishikimi T, Teragaki M, Yasuda M, Oku H, Takeuchi K, Takeda T (1988) Influence of nisoldipine on hemodynamics and atrial natriuretic polypeptides at exercise loading in hypertensive patients. Clin Rep 22: 4841-4852
26. Suzuki S, Morimoto I (1989) Pharmacokinetic study of manidipine hydrochloride, a Ca-antagonist, in patients with essential hypertension after repeated doses. Clin Rep 23: 5043-5053
27. Hashimoto K, Motomura S, Tsujimoto G, Higuchi S, Teramura T (1990) Phase I study of a calcium antagonist, YM730 (mepirodipine hydrochloride). Clin Rep 24: 4443-4458
28. Nakashima M, Kanamaru M, Uematsu T, Shimooka K, Sawada Y, Tatematsu H (1991) Phase I study of amlodipine besilate, a new calcium channel blocker in healthy volunteers. Rinsyoiyaku 7: 1407-1435
29. Scherling D, Ahr G, Karl W (1987) Biotransformation of nisoldipine in man. In: Hungenholtz PG, Meyer J (eds) Nisoldipine. Springer, Berlin Heidelberg New York, pp 85-88
30. Higuchi S, Shiobara Y (1980) Metabolic fate of nicardipine hydrochloride, a new vasodilator, by various species in vitro. Xenobiotica 10: 889-896
31. Rosenkranz H, Schlossmann K, Scholtan W (1974) Die bindung von 4-(2′-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarbonsäuredimethylester (nifedipine) sowie von anderen koronarwirksamen stoffen an die eiweißkörper des serums. Arzneimittelforschung 24: 455-466
32. Schlossmann K, Medenwald H, Rosenkranz H (1975) Investigations on the metabolism and protein binding of nifedipine. In: Proceedings of 2nd International Adalat Symposium, pp 33-39
33. Yoshida K, Mitani M, Tsukamoto T, Naeshiro I, Shiraishi A, Yagi K, Kimura T, Shimomura H, Tanayama S (1989) Disposition of manidipine hydrochloride [CV-4093 (2HCl)], a new calcium antagonist, in rats and dogs. Jpn Pharmacol Ther 17: 2083-2117
34. Yamamoto Y, Uda K, Mita A, Matsushita H, Sindoh T, Matsushima E, Yoshida K, Nishizaki J, Umeno Y, Nagasaka M, Momose Y, Nishigaki J, Motoji N, Shigematsu A (1993) Pharmacokinetic studies of MPC-1304 (4): dose response, animal differences, protein binding. Jpn Pharmacol Ther 21: 1223-1236
35. Tjia JF, Back DJ, Breckenridge AM (1989) Calcium channel antagonists and cyclosporine metabolism: in vitro studies with human liver microsomes. Br J Clin Pharmacol 28: 362-365
36. Ameer B, Weintraub RA (1997) Drug interactions with grapefruit juice. Clin Pharmacokinet 33: 103-121
37. Jalava KM, Olkkola KT, Neuvonen PJ (1997) Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin Pharmacol Ther 61: 410-415
38. Bourbigot B, Guiserix J, Airiau J, Bressollette L, Morin JF, Cledes J (1986) Nicardipine increases cyclosporine blood levels. Lancet 1: 1447
39. Henricsson S, Lindholm A (1988) Inhibition of cyclosporine metabolism by other drugs in vitro. Transplant Proc 20: 569-571